Saturday, December 20, 2014

Cynapsus to uplist to TSX on Nov. 28

Cynapsus to uplist to TSX on Nov. 28

November 25, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX:CTH) will begin trading on the Toronto Stock Exchange at the opening this Friday, Nov. 28. The shares will continue to trade under the symbol CTH. Trading on the TSX Venture Exchange will end on Friday. The change does not affect trading on the OTCQX International in the U.S. “Uplisting the […]

Cynapsus posts positive top-line PD results

Cynapsus posts positive top-line PD results

November 19, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive top-line results from its CTH-105 Phase 2 clinical trial of APL-130277 for the management of OFF motor symptoms of Parkinson’s disease (PD), which leave patients rigid and unable to move and communicate. Out of 16 patients treated with APL-130277, a fast-acting, sublingual, thin filmstrip formulation of apomorphine, […]

Cynapsus’ APL-130277 one of  “Top Ten Neurology Projects to Watch”

Cynapsus’ APL-130277 one of “Top Ten Neurology Projects to Watch”

October 14, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics’ (OTCQX:CYNAF; TSX-V:CTH) APL-130277 drug candidate for Parkinson’s disease has been recognized as one of the “Top Ten Neurology Projects to Watch” by a joint selection committee. The committee included Dr. Harry Tracy, a noted authority on pharmacological interventions for diseases of the brain. Dr. Tracy is also the editor of the biotechnology publication, […]

Cynapsus names Dr. Thierry Bilbault as CSO, EVP

Cynapsus names Dr. Thierry Bilbault as CSO, EVP

October 7, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Dr. Thierry Bilbault, as CSO and EVP of chemistry, manufacturing and controls (CMC). In this role, Dr. Bilbault will lead the strategic CMC activities related to the company’s APL-130277 drug candidate, a convenient and easy to use sublingual thin filmstrip for the rescue of “off” motor symptoms of […]

Cynapsus appoints Ernst & Young as auditor

Cynapsus appoints Ernst & Young as auditor

September 19, 2014 by · Leave a Comment 

Tweet The board of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has appointed Ernst & Young as auditor for the company, effective immediately, replacing McGovern, Hurley, Cunningham, which resigned at the request of the company. In a statement, Cynapsus said there were no reservations in the former auditor’s reports in connection with the two most recently completed fiscal […]

Cynapsus to start Phase 2 trial of APL-130277


Cynapsus to start Phase 2 trial of APL-130277


July 17, 2014 by · Leave a Comment 

Tweet Following communication from the FDA, Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) announced that it will begin Phase 2 clinical studies for APL-130277 immediately. The CTH-105 study will be initiated according to a proposal submitted to the FDA under the company’s IND application. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug […]

Cynapsus gets additional grant from MJFF

Cynapsus gets additional grant from MJFF

July 8, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has been awarded a new grant of $500,000 from the Michael J. Fox Foundation (MJFF) for Parkinson’s research to support clinical studies to develop APL-130277, a sublingual thin film strip reformulation of apomorphine. This is the second grant that Cynapsus has received from the MJFF and will be used to fund […]

Three BT-featured CEOs sweep EY award finalist selections

Three BT-featured CEOs sweep EY award finalist selections

July 7, 2014 by · Leave a Comment 

Tweet All three finalists for the EY 2014 Ontario Entrepreneur of the Year award in the health sciences category have been featured in the past on BioTuesdays.com. They are Anthony Giovinazzo of Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH), Tom Reeves of closely held Interface Biologics and Dr. Arun Menawat of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ). The Ontario winners will be announced […]

Cynapsus sees no irritation in APL-130277 animal test

Cynapsus sees no irritation in APL-130277 animal test

May 14, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) says there was no irritation observed when testing its APL-130277 sublingual apomorphine formulation in a buccal mucosal irritation model in hamsters, either macroscopically by a clinician or microscopically. “The data, coupled with our clinical results to date, continue to validate the design of our thin-film strip technology,” president and CEO […]

Cynapsus reports positive study data for APL-130277

Cynapsus reports positive study data for APL-130277

April 24, 2014 by · Leave a Comment 

Tweet Cynapsus Therapeutics (OTCQX:CYNAF; TSX-V:CTH) has released positive data from its recently completed CTH-104 healthy volunteer pilot study of a single, 25-milligram sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the U.S., Europe, Japan and other countries for the acute rescue of […]

Next Page »

Email Newsletters with Constant Contact
Google+